Global Transthyretin Amyloidosis Treatment Market Size & Outlook
Global transthyretin amyloidosis treatment market, 2018-2030 (US$M)
Related Markets
Global transthyretin amyloidosis treatment market highlights
- The global transthyretin amyloidosis treatment market generated a revenue of USD 4,718.0 million in 2021 and is expected to reach USD 8,044.4 million by 2028.
- The market is expected to grow at a CAGR (2022 - 2028) of 7.9% by 2028.
- In terms of segment, attr-cm accounted for a revenue of USD 3,877.1 million in 2021.
- ATTR-PN is the most lucrative type segment registering the fastest growth during the forecast period.
- In terms of region, North America was the largest revenue generating market in 2021.
- Country-wise, U.S. is expected to register the highest CAGR from 2022 to 2028.
Global data book summary
| Market revenue in 2021 | USD 4,718.0 million |
| Market revenue in 2028 | USD 8,044.4 million |
| Growth rate | 7.9% (CAGR from 2021 to 2028) |
| Largest segment | Attr-cm |
| Fastest growing segment | ATTR-PN |
| Historical data covered | 2018 - 2020 |
| Base year for estimation | 2021 |
| Forecast period covered | 2022 - 2028 |
| Quantitative units | Revenue in USD million |
| Market segmentation | ATTR-PN, ATTR-CM |
Other key industry trends
- In terms of revenue, the North America accounted for 68.2% of the global transthyretin amyloidosis treatment market in 2021.
- By country, the U.S. is projected to lead the global market in terms of revenue in 2028.
- By country, U.S. is the fastest growing regional market and is projected to reach USD 5,049.5 million by 2028.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Transthyretin Amyloidosis Treatment Market Scope
Transthyretin Amyloidosis Treatment Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Global transthyretin amyloidosis treatment market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to transthyretin amyloidosis treatment market will help companies and investors design strategic landscapes.
Attr-cm was the largest segment with a revenue share of 82.18% in 2024. Horizon Databook has segmented the Global transthyretin amyloidosis treatment market based on attr-pn, attr-cm covering the revenue growth of each sub-segment from 2018 to 2030.
- Global Transthyretin Amyloidosis Treatment Therapy Outlook (Revenue, USD Million, 2018-2030)
- Targeted Therapy
- Vyndaqel/ Vyndamax
- Onpattro
- Amvuttra
- Tegsedi
- Wainua
- Supportive Therapy
- Pipeline Therapy
- Targeted Therapy
- Global Transthyretin Amyloidosis Treatment Type Outlook (Revenue, USD Million, 2018-2030)
- ATTR with Polyneuropathy (ATTR-PN)
- ATTR with Cardiomyopathy (ATTR-CM)
- Global Transthyretin Amyloidosis Treatment Disease Type Outlook (Revenue, USD Million, 2018-2030)
- Hereditary Transthyretin Amyloidosis
- Polyneuropathy
- Cardiomyopathy
- Mixed Type
- Wild Type Amyloidosis
- Hereditary Transthyretin Amyloidosis
- Global Transthyretin Amyloidosis Treatment Distribution Channel Outlook (Revenue, USD Million, 2018-2030)
- Hospital Pharmacies
- Specialty Pharmacies
- Retail Pharmacies
- Online Pharmacies
Reasons to subscribe to Global transthyretin amyloidosis treatment market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Global transthyretin amyloidosis treatment market databook
-
Our clientele includes a mix of transthyretin amyloidosis treatment market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of global-level data and insights on the Global transthyretin amyloidosis treatment market , including forecasts for subscribers. This global databook contains high-level insights into Global transthyretin amyloidosis treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Global transthyretin amyloidosis treatment market size, by region, 2018-2028 (US$M)
Top 10 countries: Transthyretin amyloidosis treatment market size, 2021 (US$M)
Global transthyretin amyloidosis treatment market share, by type, 2021 & 2028 (%, US$M)
Transthyretin amyloidosis treatment market: Opportunity assessment by country
Global transthyretin amyloidosis treatment market, by region, 2024 (US$M)
| Type | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | CAGR |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| North America | 440.0 | 1,056.1 | 2,335.6 | 3,217.9 | 3,459.2 | 3,677.8 | 3,927.5 | 4,191.8 | 4,475.4 | 4,781.0 | 5,104.3 | 6.8% |
| Europe | 120.7 | 296.4 | 466.0 | 679.7 | 747.5 | 808.8 | 871.2 | 952.0 | 1,038.8 | 1,132.3 | 1,236.5 | 8.9% |
| Asia Pacific | 111.4 | 266.2 | 521.9 | 686.4 | 745.4 | 792.1 | 846.4 | 902.6 | 973.0 | 1,044.7 | 1,119.4 | 7.2% |
| Latin America | 35.3 | 52.8 | 70.3 | 69.7 | 83.0 | 98.0 | 118.9 | 144.4 | 182.4 | 228.2 | 284.6 | 22.3% |
| MEA | 39.2 | 50.8 | 63.6 | 64.4 | 75.7 | 88.9 | 109.0 | 134.2 | 176.1 | 229.7 | 299.7 | 24.6% |
| Overall | 746.7 | 1,722.4 | 3,457.4 | 4,718.0 | 5,110.9 | 5,465.4 | 5,873.1 | 6,325.0 | 6,845.7 | 7,416.0 | 8,044.4 | 7.9% |
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
